Development and validation of an HPLC method for the determination of process-related impurities in pridinol mesylate, employing experimental designs

被引:23
作者
Bianchini, Romina M.
Castellano, Patricia M.
Kaufman, Teodoro S. [1 ]
机构
[1] Natl Univ Rosario, Sch Pharmaceut & Biochem Sci, Dept Organ Chem, Rosario, Santa Fe, Argentina
关键词
Pridinol mesylate; Manufacturing process impurities; HPLC method development; Method validation; Experimental design; Quality control; LOW-BACK-PAIN; MUSCLE-RELAXANTS; DRUGS;
D O I
10.1016/j.aca.2009.09.022
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A simple high performance liquid chromatographic method for the determination of process-related impurities in bulk drug of the central anticholinergic compound pridinol mesylate. has been developed and validated. Spectroscopically characterized synthetic impurities were used as standards. The chromatographic separation was optimized employing an experimental design strategy, and was achieved on a C-18 column with a mobile phase containing 50 mM potassium phosphate buffer (pH 6.4), MeOH and 2-propanol (20:69:11, v/v/v), delivered at a flow rate of 1.0 mL min(-1). UV detection was performed at 245 nm. The optimized method was thoroughly validated, demonstrating to be selective, when the chromatogram was recorded with a diode-array detector and peak purities were evaluated (>0.9995). The method is robust and linear (r(2) > 0.99) over the range 0.05-2.5% (5-250% with regards to the 1% specification limit for both process-related impurities); it is also precise, regarding repeatability (RSD <= 1.5% for all of the analytes) and intermediate precision aspects and LOQ values for the impurities are below 0.01%. Method accuracy. evidenced by low bias of the results and analyte recoveries in the range of 99.1-102.7%, was assessed at five analyte concentration levels. The usefulness of the determination was also demonstrated through the analysis of different lots of pridinol mesylate bulk substance. The results indicate that the method is suitable for the quality control of the bulk manufacturing of pridinol mesylate drug Substance. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 26 条
  • [1] Assuring quality of drugs by monitoring impurities
    Ahuja, Satinder
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (01) : 3 - 11
  • [2] Strategies for the investigation and control of process-related impurities in drug substances
    Argentine, Mark D.
    Owens, Paul K.
    Olsen, Bernard A.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (01) : 12 - 28
  • [3] Validated stability-indicating HPLC method for the determination of pridinol mesylate. Kinetics study of its degradation in acid medium
    Bianchini, Romina M.
    Castellano, Patricia M.
    Kaufman, Teodoro S.
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 48 (04) : 1151 - 1160
  • [4] BLICKE FF, 1942, ORGANIC REACTIONS, V1
  • [5] DERRINGER G, 1980, J QUAL TECHNOL, V12, P214, DOI 10.1080/00224065.1980.11980968
  • [6] Eisleb O, 1953, DE, Patent No. 875660
  • [7] Epshtein N.A., 2004, Pharmaceutical Chemistry Journal, V38, P212
  • [8] FASSINA A, 1986, INT J CLIN PHARM RES, V6, P501
  • [9] FOLEY PB, 2001, THESIS BJ MAXIMILIAN
  • [10] *H MAJ STAT OFF, 2007, BRIT PHARM